Entrada Therapeutics, Inc.
TRDAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEntrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that. The company carries a $267.5M market cap, placing it firmly in the micro-cap category. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Market Cap
$267.5M
Beta
-0.26
P/E (TTM)
—
P/E (Fwd)
-2.12
EPS (TTM)
$-4.00
EPS (Fwd)
$-3.26
ROE
-48.3%
ROA
-26.8%
Cash
$254.9M
Total Debt
$49.8M
Free CF
-$75.4M
52W Change
10.1%
Annual Financials
Cash vs Debt
Entrada Therapeutics, Inc. holds $254.9M in cash against $49.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$75.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.26 suggests TRDA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Entrada Therapeutics, Inc. and its sector.